| アブストラクト | INTRODUCTION: Isavuconazole, a broad-spectrum triazole approved by the United States Food and Drug Administration (FDA) in 2015, moderately inhibits cytochrome P450 3A4. Although antifungal agents are often used concomitantly with cyclosporine, the effect of switching from voriconazole to isavuconazole on the blood cyclosporine level remains unclear. CASE: A 63-year-old Japanese male was administered oral cyclosporine (10:00 and 21:00) for severe aplastic anemia. Following pneumonia with positive Aspergillus antigen and an elevated beta-D-glucan level, antifungal therapy was initiated. After switching from voriconazole (10:00 and 21:00) to isavuconazole (approximately 08:00), the blood cyclosporine level decreased by more than half. Although the blood cyclosporine level decreased after switching to isavuconazole, the dose of cyclosporine was not increased because of its possible effect on renal function. Considering the inhibitory effects on the gastrointestinal tract, a physiologically based pharmacokinetic analysis estimated that isavuconazole increased the area under the curve (AUC) and C (max) of cyclosporine by 1.48-fold and 1.84-fold, respectively, although assuming no change in gastrointestinal metabolism, these effects were minimal. For interaction with voriconazole considering gastrointestinal metabolism, the predicted increases in AUC and C (max) were 3.74-fold and 3.86-fold, respectively. The FDA Adverse Event Reporting System database included 9,144 reports on cyclosporine and 174 on cyclosporine with voriconazole, but none concomitant with isavuconazole. The reporting odds ratios for cyclosporine and isavuconazole could not be assessed because of insufficient reports. CONCLUSION: The interaction of isavuconazole with cyclosporine was weaker than that with voriconazole. Maintaining a two-hour dosing interval between isavuconazole and cyclosporine may minimize gastrointestinal drug interactions. |
|---|
| ジャーナル名 | Frontiers in microbiology |
|---|
| Pubmed追加日 | 2025/3/11 |
|---|
| 投稿者 | Shiraishi, Chihiro; Kato, Hideo; Ino, Kazuko; Iwamoto, Takuya |
|---|
| 組織名 | Department of Pharmacy, Mie University Hospital, Mie, Japan.;Division of Clinical Medical Science, Department of Clinical Pharmaceutics, Mie;University Graduate School of Medicine, Mie, Japan.;Department of Hematology and Oncology, Faculty of Medicine, Mie University;Hospital, Mie, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40066270/ |
|---|
